Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

• Colin Reisner,
• Leonardo M. Fabbri,
• Edward M. Kerwin,
• Charles Fogarty,
• Selwyn Spangenthal,
• Klaus F. Rabe,
• Gary T. Ferguson,
• Fernando J. Martinez,
• James F. Donohue,
• Patrick Darken,
• Earl St. Rose,
• Chad Orevillo,
• Shannon Strom,
• Tracy Fischer,
• Michael Golden,
• Sarvajna Dwivedi

Affiliations

Colin Reisner

Pearl Therapeutics Inc.

Leonardo M. Fabbri

Department of Medicine

Edward M. Kerwin

Clinical Research Institute of Southern Oregon

Charles Fogarty

Spartanburg Medical Research

Selwyn Spangenthal

American Health Research

Klaus F. Rabe

Lungen Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL)

Gary T. Ferguson

Pulmonary Research Institute of Southeast Michigan

Fernando J. Martinez

Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College; New York-Presbyterian Hospital/Weill Cornell MedicalCenter

James F. Donohue

Department of Medicine, University of North Carolina School of Medicine

Patrick Darken

Pearl Therapeutics Inc.

Earl St. Rose

Pearl Therapeutics Inc.

Chad Orevillo

Pearl Therapeutics Inc.

Shannon Strom

Pearl Therapeutics Inc.

Tracy Fischer

Pearl Therapeutics Inc.

Michael Golden

Pearl Therapeutics Inc.

Sarvajna Dwivedi

Pearl Therapeutics Inc.